Ethical considerations concerning treatment allocation in drug development trials
From MaRDI portal
Publication:5424156
DOI10.1191/0962280202sm299razbMath1121.62661OpenAlexW2062336256WikidataQ30332007 ScholiaQ30332007MaRDI QIDQ5424156
No author found.
Publication date: 2 November 2007
Published in: Statistical Methods in Medical Research (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1191/0962280202sm299ra
Related Items (17)
Notes on testing equality in binary data under a three period crossover design ⋮ Test and estimation in binary data analysis under an incomplete block crossover design ⋮ Maximin efficiencies under treatment-dependent costs and outcome variances for parallel, AA/BB, and AB/BA designs ⋮ The finite sample performance of the two-stage analysis of a two-period crossover trial ⋮ Bayesian crossover designs for generalized linear models ⋮ Notes on power comparison between the sequential parallel comparison and other commonly-used designs ⋮ Notes on the two-stage procedure under an incomplete block two-period crossover design ⋮ Notes on misspecifying the random effects distribution regarding analysis under the AB/BA crossover trial in dichotomous data – a Monte Carlo evaluation ⋮ Robustness and monotonicity properties of generalized correlation coefficients ⋮ A Bayesian analysis of the incomplete block crossover design ⋮ Estimation of the proportion ratio under a simple crossover trial ⋮ Notes on estimation in Poisson frequency data under an incomplete block crossover design ⋮ A review of uniform cross-over designs ⋮ On wide sense stationary processes over finite non-abelian groups ⋮ Nonparametric approaches to the analysis of crossover studies ⋮ Group sequential crossover trial designs with strong control of the familywise error rate ⋮ On uniformly balanced crossover designs efficient under subject dropout
Cites Work
This page was built for publication: Ethical considerations concerning treatment allocation in drug development trials
